Vasopressin Antagonist [EPC]

Known as: Vasopressin Receptor Antagonist, Vasopressin Receptor Antagonist [EPC] 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2014
0119982014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
The publication of the guideline by the European Renal Best Practice (ERBP) group has helped stimulate a debate on this important… (More)
Is this relevant?
Review
2012
Review
2012
Hyponatremia in critically ill patients is a common and challenging problem. Increased levels of arginine vasopressin almost… (More)
Is this relevant?
2008
2008
Hyponatremia is a common and challenging disorder. The mainstays of treatment until recently were water restriction and… (More)
Is this relevant?
2007
2007
Das Ausmaß der mikrovaskulären Schädigung spielt eine zentrale Rolle in der Pathogenese der Sepsis. Es wird durch endotheliale… (More)
Is this relevant?
Review
2006
Review
2006
The first non-peptide vasopressin receptor antagonist (VRA) was recently approved by the United States Food and Drug… (More)
Is this relevant?
2001
2001
BACKGROUND AND PURPOSE We sought to investigate the effects of EPC-K1, a free radical scavenger, on reducing heparin-produced… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
1998
1998
During puberty, primates begin to secrete LH, and presumably GnRH, at night and then eventually throughout the day as they mature… (More)
Is this relevant?